Intravitreal infliximab for choroidal neovascularization in patients refractory to conventional treatments.
The aim of the study is to evaluate the effectiveness and safety of intravitreal infliximab in the course of compassionate use in patients affected by choroidal neovascularization. This prospective interventional case series includes four eligible patients, affected by exudative age-related macular degeneration (2/4), retinal angiomatous proliferation (1/4) and central retinal vein occlusion (1/4), who were refractory to conventional treatments. The patients received a single intravitreal injection of 0.05 ml of reconstituted infliximab solution (20mg/ml). The main outcomes measure were changes in best-corrected visual acuity and central retinal thickness. Patients were evaluated at baseline, every week for the first month, then every two weeks, and on demand. Morphologic parameters improved after a single infliximab intravitreal injection. However, all patients developed acute uveitis in a period ranging from 4 to 7 weeks after treatment. Control of the intraocular inflammation was achieved with topical and systemic steroids in 3 patients, whereas in one case pars plana vitrectomy was needed. A single intravitreal injection of infliximab does not seem to improve the natural history of CNV from different aetiologies. However, all patients in our series developed a serious inflammatory response that required surgical management in one case. The intravitreal administration of infliximab is hence not safe and not recommended in clinical practice.
Dipartimento di Oftalmologia, Universita degli Studi di Brescia, Brescia, Italy.
F
F
Semeraro
M R
MR
Romano
P
P
Danzi
M
M
Angi
C
C
Costagliola
D000368:Aged; D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D057176:Compassionate Use Trials; D005260:Female; D006801:Humans; D000069285:Infliximab; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000150:complications; D008297:Male; D011446:Prospective Studies; D012160:Retina / Q000187:drug effects / Q000473:pathology; D012170:Retinal Vein Occlusion / Q000150:complications; D013256:Steroids / Q000008:administration & dosage; D013997:Time Factors; D016896:Treatment Outcome; D014605:Uveitis / Q000139:chemically induced / Q000175:diagnosis / Q000628:therapy; D014792:Visual Acuity / Q000187:drug effects; D014821:Vitrectomy; D006623:von Hippel-Lindau Disease / Q000150:complications
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D013256:Steroids; D000069285:Infliximab